Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin.
OBJECTIVE
We hypothesized that body composition would be similar among neonates of women with gestational diabetes (GDM) treated with glyburide or insulin.


METHODS
Women with GDM requiring medical therapy were randomized to insulin or glyburide. The primary outcome was percent neonatal fat mass measured by total body electrical conductivity. Secondary outcomes included anthropometrics, glycemic control, and biomarkers. Statistical analysis included Student t test, chi(2), and regression modeling.


RESULTS
Eighty-two neonates underwent postnatal measurements. Baseline factors were not different by group. Neonatal percent fat mass did not differ between treatment groups (11.2 +/- 4.2 vs 12.8 +/- 5.7). Fat mass, body mass index, ponderal index, skinfold sum, and arm fat area were not different when analyzed by intent to treat or actual treatment group. Cord concentrations of biomarkers were also similar.


CONCLUSIONS
There was no difference in neonatal adiposity in infants of women treated for GDM with glyburide or insulin.
Lain
Kristine Y
KY
Department of Obstetrics and Gynecology, University of Kentucky College of Medicine, Lexington, KY 40536-0293, USA.
Garabedian
Matthew J
MJ
Daftary
Ashi
A
Jeyabalan
Arun
A
D000273:Adipose Tissue / Q000187:drug effects*; D000328:Adult; D001724:Birth Weight / Q000187:drug effects; D001823:Body Composition / Q000187:drug effects; D049628:Body Size / Q000187:drug effects; D016640:Diabetes, Gestational / Q000188:drug therapy*; D005260:Female; D005320:Fetal Macrosomia; D005905:Glyburide / Q000008:administration & dosage*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007231:Infant, Newborn; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D011247:Pregnancy; D047928:Premature Birth; D011297:Prenatal Exposure Delayed Effects
D007004:Hypoglycemic Agents; D007328:Insulin; D005905:Glyburide